Navigation Links
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Date:5/21/2008

of 48 weeks. Patients in any arm of this study with detectable virus at week 24 will be considered treatment failures and will discontinue treatment.

The primary efficacy endpoint of the study is sustained virologic response (SVR).(1) Secondary efficacy endpoints include early virologic response in patients who achieve SVR. The study will be stratified by HCV genotype 1 subtype 1a versus 1b, and baseline viral load.

Professor Jean-Pierre Bronowicki, M.D., Ph.D., department of hepato-gastroenterology, University Hospital of Nancy, France, and Jonathan McCone, M.D., director, Mount Vernon Endoscopy Center, Alexandria, Va., are the other co-principal investigators of this study.

Pivotal Study in Patients Who Failed Prior Treatment

The primary objective of this pivotal study, known as HCV RESPOND-2 (Retreatment with HCV Serine Protease Inhibitor Boceprevir and PEGINTRON/REBETOL) is to evaluate the efficacy of 36- and 48-week regimens of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg/week) and REBETOL (600-1400 mg/day) compared to a control of PEGINTRON and REBETOL alone for 48 weeks in adult patients with chronic HCV genotype 1 who failed prior treatment with peginterferon and ribavirin combination therapy. The study is projected to enroll a total of 375 patients.

This study will enroll treatment-failure patients who have documented previous interferon responsiveness by achieving at least a 2 log decrease in viral load by week 12 of peginterferon and ribavirin therapy (nonresponders) or who were viral negative at end of peginterferon and ribavirin therapy, but did not obtain a sustained virologic response (relapsers). 'Null' responders -- those patients who do not meet the aforementioned criteria -- will not be enrolled in this study.

In this study, in the 36-week treatment arm, RVR criteria at 4 weeks of boceprevir treatment (treatment week 8) will be used to determine which boceprevir patients can stop all
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Schering-Plough Reports Top-Line Results of the IDEAL Study
7. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
8. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
11. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)...  Today, in final recognition of the Centers for ... 1-800 Contacts is sharing how to keep lens cases ... who do not properly care for their lens cases ... Most contact lens wearers understand the importance ... case is sometimes overlooked.  When proper steps to clean ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... The Cleveland Clinic and Valence Health announced today that ... become a clinically integrated network.  This new network, the ... physicians, and more than 1,000 private practitioners in the ... Physician Partnership (CPP), recognized the need to pursue Clinical ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), ... accelerating the development and enhancing the value of oncology ... Chief Financial Officer. Mr. Schonau indicated that he has ... other opportunities. Champions is seeking chief financial officer candidates ...
Cached Medicine Technology:Valence Health Selected by Cleveland Clinic to Support Clinical Integration Program 2Champions' CFO Resigns 2
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products ... lead the expansion of global cosmeceutical and skin care brands. Mr. Fernandez ... the last 25 years working in operations, purchasing and management for some of ...
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... ... Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... than a simple digital handwritten signature. , Clinical trial sites can ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder ... mission is to increase acceptance of the chiropractic field in the military. All too ... them. Although Chiropractic was made available to the VA program over a decade ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also ... shown through research to improve treatment outcomes. This localized treatment seems to ...
(Date:8/28/2015)... Nevada (PRWEB) , ... August 28, 2015 , ... An ... its decision to make the purchase of CPAP equipment more affordable by offering shipping ... includes all types of CPAP products and orders of any size. My Cpap Store ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2
... to smoke or consume high doses of caffeine ... the disease//, according to a report. ... (NSAID) medications (such as aspirin, ibuprofen and naproxen) ... Parkinson's disease, according to background information in the ...
... published in the April 10, 2007, issue of Neurology, ... patients// suffering ‘Restless Legs Syndrome (RLS). The risk increases ... conducted at the University of Montreal’s Sacré-Coeur Hospital, ten ... sleep laboratory, where researchers monitored periodic leg movements and ...
... Canadian report has come out with news that would gladden ... as strike fear// in the minds of their western ... of the McLaughlin-Rotman Center for Global Health in Toronto, Canada, ... and ill health". The report published in ...
... by Banfield, The Pet Hospital, one of the largest chains ... dogs// were sickened or killed nationwide consequent on pet food-contamination ... reportedly compiled from records collected from more than 615 veterinary ... contaminated pet food. Described as one of the largest in ...
... from one moment to the next, and experts say the ... psychological after-effects. ,"Every person reacts differently to shock," ... services in the northern German port city of Hamburg. ... screaming is seldom the case, she says. "Some people are ...
... to the U.S. Department of Energy's Brookhaven National Laboratory ... the U.S. Patent Number 7,179,448 which will allow them ... the development of vaccines and diagnostic tests for Lyme ... of two proteins that are normally present on the ...
Cached Medicine News:Health News:Smoking and Caffeine Inversely Associated With Parkinson's Disease 2Health News:Restless Legs Syndrome Poses Risk of Cardiovascular Disease 2Health News:India’s Biotech Companies- Jumbos Waiting to Gro 2Health News:Melamine Contamination Killed Thousands of Pets, Says a New Report 2Health News:Accident Victims Often Need Psychological Help 2Health News:Scientists Receive Patent for Development of "combination" Proteins to Produce Vaccines for Lyme Disease 2Health News:Scientists Receive Patent for Development of "combination" Proteins to Produce Vaccines for Lyme Disease 3
Large, bright images from a bronchoscope designed for routine examination and treatment....
... The BF-1T40 has been designed with ... versatility in therapeutic applications. This permits the ... including those for electrosurgical procedures. In addition, ... wide field of view and a bright, ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... scope designed specifically to enable direct inspection ... suitable for pediatric applications as well. Its ... mere 2.8mm across. As a result, insertion ... with greater ease. And since this sophisticated ...
Medicine Products: